ЭЛЛИС Джеймс Лэмонд (US),ЭВАНС Карен Андерсон (US),ФОКС Райан Майкл (US),МИЛЛЕР Уилльям Генри (US),СИФЕЛД Марк Эндрю (US)
申请号:
RU2017120857
公开号:
RU2017120857A
申请日:
2015.11.19
申请国别(地区):
RU
年份:
2018
代理人:
摘要:
The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.